Back to Search
DAVID BROWN, PH.D
PH.D
Marriage & Family Therapist
NPI: 1467578427Individual
Specialties, Licenses & Credentials
Clinical Trials (1)
1
Linked Trials
0
Recruiting
1
With Results
Research & Publications (20)
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
PMID 24518078·Br J Ophthalmol·2014
4-observational
Aflibercept (eylea) for age-related macular degeneration.
PMID 22354219·Med Lett Drugs Ther·2012
6-review
Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration.
PMID 22300011·Expert Opin Pharmacother·2012
6-review
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.
PMID 21526923·N Engl J Med·2011
4-observational
Fundus autofluorescence and visual acuity in central serous chorioretinopathy.
PMID 21055816·Ophthalmology·2011
8-other
Vascular endothelial growth factor Trap-Eye for diabetic macular oedema.
PMID 19174397·Br J Ophthalmol·2009
8-other
Predicted biological activity of intravitreal VEGF Trap.
PMID 18356264·Br J Ophthalmol·2008
4-observational
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
PMID 17386270·Am J Ophthalmol·2007
3-trial
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
PMID 17021319·N Engl J Med·2006
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4447 E BROADWAY RD STE 108
MESA, AZ 85206 - Phone
- (480) 641-9700
Quick Facts
- NPI
- 1467578427
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile